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   The binding of a lophine-based fluorescence probe, 21 
4-[4-(4-dimethylaminophenyl)-5-phenyl-1H-imidazol-2-yl]benzoic acid methyl ester (DAPIM) 22 
with human serum albumin (HSA) was investigated by fluorescence spectroscopy under 23 
physiological conditions.  While DAPIM shows extreme low fluorescence in aqueous solution, 24 
DAPIM binding with HSA emits strong fluorescence at 510 nm.  The binding constant and 25 
binding number determined by Scatchard plot was 3.65 x 106 M-1 and 1.07, respectively.  26 
Competitive binding between DAPIM and other ligands such as warfarin, valproic acid, diazepam 27 
and oleic acid, were also studied fluorometrically.  The results indicated that the primary binding 28 
site of DAPIM to HSA is site II at subdomain IIIA.  DAPIM can be a useful fluorescence probe 29 
for the characterization of drug-binding sites.  In addition to the interaction study, because the 30 
fluorescence intensity of DAPIM increased in proportion to HSA concentration, its potential in 31 
HSA assay for serum sample was also evaluated. 32 
 33 
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   Human serum albumin (HSA) is the most abundant protein constituent of blood and serves as a 37 
protein storage component.  Its principal function is to bind and transport a wide variety of 38 
bioactive molecules such as fatty acids, hormones, vitamins and numerous pharmaceuticals [1, 2].  39 
The main regions of HSA for ligand binding are located in hydrophobic cavities in the subdomains 40 
IIA (site I) and IIIA (site II) [3-5].  The binding affinity of a drug to HSA affects the distribution, 41 
pharmacokinetics, toxicity and rate of excretion of the drug [4].  Therefore, information on the 42 
binding affinity of a drug and biomolecule to HSA is particularly useful for solving in vivo 43 
pharmaceutical problems [6]. 44 
   The spectroscopic techniques are of great help in the study of interactions between small 45 
molecules and HSA.  Among them, fluorescence spectroscopy can provide an important 46 
information for the structure and the microenvironment based on the characteristics of emission, 47 
fluorescence polarization and energy transfer.  A variety of fluorescent probes have been used for 48 
studies of the characteristics of ligand binding and binding sites of HSA, competitive binding of 49 
other ligands, and the spatial relationship between Trp-214 and the probe-binding [7-15]. 50 
   On the other hand, there is a connection between the content of HSA in urine or blood and some 51 
diseases, such as nephropathy, so the determination of HSA is very important in clinical diagnosis.  52 
Many methods have been described for the determination of HSA.  Various compounds such as 53 
bromocresol green (BCG) and bromocresol purple (BCP) have been reported as analytical reagents 54 
based on changes in their colors by binding to HSA [16-18].  BCG and BCP methods are most 55 
widely used for HSA assay in clinical laboratory [19, 20]. 56 
   Until now, we reported several analytical methods for biologically important compounds by 57 
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employing the fluorescence and chemiluminescence properties of lophine derivatives mainly as a 58 
labeling reagent [21-27].  During these studies, we discovered that a lophine derivative, 59 
4-[4-(4-dimethylaminophenyl)-5-phenyl-1H-imidazol-2-yl]benzoic acid methyl ester (DAPIM, Fig. 60 
1) has almost no fluorescence, but the fluorescence intensity of DAPIM solution was drastically 61 
enhanced by the addition of HSA in aqueous solvent [21], which may be a result of the interaction 62 
between DAPIM and HSA.  In this paper, in order to systematically explore the binding 63 
mechanism of DAPIM with HSA, the binding characteristics were discussed by determining the 64 
binding constant and binding sites under physiological conditions.  Also, we evaluated its potential 65 
as a fluorescence probe for determination of HSA in human serum. 66 
 67 
Materials and methods 68 
Reagents and apparatus 69 
   HSA and warfarin were purchased from Sigma (St. Louise, MO, USA).  Diazepam, valproic 70 
acid, BCG and oleic acid were obtained from Wako (Osaka, Japan).  DAPIM was synthesized 71 
according to our previous report [21].  Fluorescence was measured with a Shimadzu RF-1500 72 
spectrofluorometer (Kyoto, Japan). 73 
 74 
General procedure 75 
Under the optimum experimental conditions, 20 µL of HSA solution and 3.0 mL of 2 mM 76 
DAPIM in pH 7.4 phosphate buffered saline (PBS, 8 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM 77 
NaCl, 2.7 mM KCl) containing 0.025% sodium dodecyl sulfate (SDS) were mixed, then were 78 
incubated at room temperature for 20 min.  The fluorescence intensity was measured with the 79 
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following settings of spectrofluorometer: excitation wavelength (λex), 370 nm; excitation slit, 10 80 
nm; emission wavelength (λem), 510 nm; emission slit, 10 nm. 81 
 82 
Circular dichroism measurement 83 
   The alterations in the secondary structure of the HSA in the presence of DAPIM with different 84 
concentrations were studied by monitoring circular dichroism (CD) spectra on a Jasco J-725 CD 85 
spectrophotometer using a rectangular quartz cuvette of path length 2 mm at 0.2 nm data pitch 86 
intervals.  All CD spectra were taken in a wavelength from 200 to 240 nm.  The 87 
spectrophotometer was sufficiently purged with 99.9% nitrogen before starting the measurement.  88 
The spectra were collected at a scan speed of 200 nm/min and a response time of 1 s.  The final 89 
plot was taken as an average of three accumulated plots. 90 
 91 
Serum samples 92 
Sera from healthy donors (n=10; 21-30 years; 5 female) were collected in our laboratory.  The 93 
whole blood was collected by tubes containing coagulation accelerator.  After removing the clot 94 
by centrifuging 1300 g for 10 min at 4°C, the resulting supernatant (serum) was stored at -80°C.  95 
The samples were diluted 10-fold with PBS (pH 7.4) and the diluents were used for HSA 96 
determination.  According to the procedures presented in previous literatures [20], 5.0 mL of BCG 97 
(150 µM) in citrate buffer (pH 4.0) was added to 25 µL of serum and then, stand at room 98 
temperature for 10 min.  An UV absorbance at 628 nm was measured by Shimadzu UV-265FS.  99 
All the experiments were performed with approval from the institutional ethics committee of the 100 




HPLC system and conditions 103 
The HPLC system consisted of two LC-6A liquid chromatographic pumps (Shimadzu, 104 
Kyoto), a F1000 fluorescence detector (Hitachi, Tokyo), a 7125 injector with a 5-µL loop 105 
(Rheodyne, Cotati, CA, USA), and a R-02A recorder (Rikadenki, Tokyo).  Chromatographic 106 
separation was performed on a Asahipak GS-520 7E (250 x 4.6 mm, i.d., Shodex, Tokyo) with a 107 
mobile phase of PBS at a flow rate of 0.5 mL/min.  The column eluent was mixed with 5 µM 108 
DAPIM in PBS as a post-column reagent at a flow rate of 0.5 mL/min, and the fluorescence was 109 
monitored at 510 nm with excitation at 370 nm.  110 
 111 
Results and discussion 112 
Fluorescence spectra characteristics of DAPIM binding to HSA 113 
   To investigate the fluorescence change upon binding of DAPIM to HSA, fluorescence titration 114 
was carried out in HSA solution with 0.2-1.0 g/dL.  Excitation and emission spectra of DAPIM in 115 
blank and HSA solution are given in Fig. 2.  The enhancement of the fluorescence of DAPIM was 116 
in proportion to the concentration of HSA.  It was reported that the fluorescence intensity was 230 117 
times higher in n-hexane than that in methanol [21]; therefore, DAPIM may bind to hydrophobic 118 
cavities in HSA and exhibit a remarkable fluorescence. 119 
 120 
Binding constant and binding site number 121 
   In order to study the interaction of small molecules with macromolecules, the Scatchard plot is 122 
commonly used to characterize the binding properties such as binding constant and number of 123 
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binding sites [28].  From the recorded fluorescence titration data, the binding constant and binding 124 
number of DAPIM with HSA were determined as 3.65 x 106 M-1 and 1.07, respectively (Fig. 3).  125 
The binding number indicates that DAPIM-HSA complex may have one binding site. 126 
 127 
Identification of the binding site 128 
   To obtain the information about the binding site of DAPIM in HSA, competitive binding 129 
between DAPIM and other ligands (i.e., warfarin, valproic acid, diazepam and oleic acid) was 130 
studied.  Warfarin, valproic acid, diazepam, and oleic acid are reported to bind to HSA at site I, 131 
site I and II, site II, and site II, respectively [29-32].  The fluorescence of DAPIM (0.05-5 µM) 132 
plus HSA (75.8 µM) was measured in the presence and the absence of other ligands (0.5 µM).  As 133 
illustrated in Fig. 4a, DAPIM was moderately displaced by diazepam, whereas the fluorescence of 134 
DAPIM bound to HSA was not affected by the other ligands.  Therefore, the site II at subdomain 135 
IIIA is the specific binding site for DAPIM.  Furthermore, the displacement by diazepam was 136 
enhanced according to an increase in its concentration (Fig. 4b).  As mentioned above, the main 137 
regions of HSA for ligand binding are located in subdomains II A (site I) and IIIA (site II); that is, 138 
DAPIM can be used as a fluorescent probe for many studies of drug-binding sites on HSA. 139 
 140 
Effect of DAPIM concentration, temperature and incubation time on the HSA assay 141 
   In order to develop HSA assay using DAPIM, several measurement conditions were optimized.  142 
The effect of the concentration of DAPIM on fluorescence intensity was investigated (Fig. 5).  At 143 
more than 1.5 µM, the maximum fluorescence intensity was obtained and 2.0 µM was chosen for 144 
further study.  Because the DAPIM-HSA complex, which provides fluorescence, might become 145 
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more unstable as temperature increased, the effect of temperature on fluorescence intensity was also 146 
studied under 298, 305, 310 and 316 K (data not shown).  As expected, temperature had a great 147 
influence on the fluorescence intensity.  The fluorescence intensity gradually decreased with 148 
increasing temperature; thus, we selected room temperature (298 K).  The incubation time of more 149 
than 20 min provided the maximum and stable fluorescence intensity. 150 
 151 
Studies on CD spectra of HSA in the presence of DAPIM 152 
  As shown in Fig. 6, the CD spectrum of HSA exhibits two negative peaks at 208 nm and 222 nm 153 
which are contributed from n → π* transition of the peptide inter linkage of α-helix [33].  The 154 
results of CD studies indicated that with the addition of DAPIM, the intensities of both the peaks 155 
slightly increased.  This indicates that certain conformational changes of HSA were occurred by 156 
the addition of DAPIM.  In addition, no change in band shape and induction of a new peak suggest 157 
that DAPIM leads to conformation structural changes but no conformational transition of HSA. 158 
 159 
Analytical characteristics 160 
   Calibration curves for determination of HSA were linear over the concentration of 0.1-0.8 g/dL 161 
(r=0.999) and the corresponding regression equation was Y=36.7X+2.2, where Y is the 162 
fluorescence intensity of DAPIM-HSA and X is the HSA concentration.  The correlation efficient 163 
(r) was greater than 0.999.  The assay parameters consisting of calibration range, slope (36.7), 164 
intercept (2.2) and the limit of detection (0.0067 g/dL, defined as the concentration corresponding 165 
to three times of the standard deviation of the background signal) were obtained.  This method 166 
exhibited good repeatability with a relative standard deviation of 1.7% obtained from six separate 167 
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determinations for 0.2 g/dL HSA. 168 
 169 
Determination of HSA in human serum 170 
   The proposed method was employed to determine HSA in human serum.  Sera obtained from 171 
healthy volunteers (n=10) were tested without pre-treatment except dilution (10-fold) by PBS.  172 
The analytical results ranged from 6.10 to 7.4 g/dL (mean ± standard deviation = 6.6 ± 0.4 g/dL).  173 
The analytical results ranged from 6.10 to 7.4 g/dL (mean ± standard deviation = 6.6 ± 0.4 g/dL).  174 
Although there have been a lot of criticism to BCG method, BCG method is still a standard method 175 
for HSA assay and is most widely used in clinical settings [19, 20, 34, 35].  Therefore, it was 176 
employed as a reference method in present study.  As shown in Fig. 7a, comparison of the 177 
proposed method with BCG assay is performed using a nonparametric Passing-Bablok analysis [36, 178 
37].  The 95% confidence interval (CI) was calculated for the slope and intercept by nonparametric 179 
Bootstrap.  The Blank-Altman approach [38-41] was used as an alternative to correlation and 180 
regression models for further assessing the difference between both methods by plotting the relative 181 
difference between the two assays versus the determined mean concentration (Fig. 7b).  182 
Regression analysis of the data yielded the following equations: proposed method = 1.05 (BCG) + 183 
0.62 [g/dL] (95% CI for slope, 0.69-1.48; 95% CI for intercept, -2.1-2.5).  In the usual linear 184 
regression model, the line of best-fit equation is calculated by minimizing the y-squared residuals.  185 
This approach assumes that there is no error on the x variable and that the y variable has a constant 186 
analytical precision.  Contrastingly, nonparametric procedures including the Passing-Bablok 187 
regression are based on the rank principle [36, 37].  This approach assumes an error on both x and 188 
y variables, a constant ratio of the variances and no special assumptions regarding the distribution of 189 
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the values.  Underestimation of the concentrations with BCG was described by some groups [42, 190 
43].  These observations were confirmed in the present study with a mean underestimation of 0.86 191 
g/dL. 192 
 193 
HPLC analysis of HSA by post-column reaction with DAPIM 194 
   HSA eluted from the gel-filtration column was mixed with DAPIM, and the generated 195 
fluorescence was monitored.  Fig. 8a shows a typical chromatogram of standard HSA solution, and 196 
the peak of HSA was detected at 20 min on the chromatogram.  Also, as shown in Fig. 8b, the 197 
peak of HSA in serum could be clearly detected without any interference from other biological 198 
components.  This result also demonstrates the excellent selectivity of DAPIM for HSA detection.  199 
Therefore, the application of DAPIM in HPLC analysis should be useful to investigate HSA 200 
analogues in complicated matrices. 201 
 202 
Conclusions 203 
   In this paper, the interaction between DAPIM and HSA has been investigated by utilizing 204 
fluorescence spectroscopy.  The binding constant to HSA is 3.65 x 106 M-1 and the primary 205 
binding site on HSA is site II at subdomain IIIA.  With its site specificity to HSA, DAPIM will be 206 
useful as fluorescence probes to elucidate the interaction between HSA and other molecules 207 
including drugs.  Based on the phenomenon that the fluorescence intensity of DAPIM was 208 
enhanced in proportion to the concentration of HSA, a novel fluorescence assay of HSA can be 209 
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Figure captions 274 
 275 
Fig. 1  Structure of 4-[4-(4-dimethylaminophenyl)-5-phenyl-1H-imidazol-2-yl]benzoic acid 276 
methyl ester (DAPIM). 277 
 278 
Fig. 2  Excitation and emission spectra of DAPIM in the presence of various concentration of 279 
HSA (0-1.0 g/dL).  The concentration of DAPIM is 5 µM. 280 
 281 
Fig. 3  Scatchard plot of DAPIM binding to HSA. 282 
 283 
Fig. 4  Effect of site marker probe on the fluorescence of DAPIM (0.05-5 µM). a) several marker 284 
probes.  b) using diazepam with different concentrations. 285 
 286 
Fig. 5  Effect of DAPIM concentration on the relative fluorescence intensity.  The concentration 287 
of HSA is 0.5 g/dL. 288 
 289 
Fig. 6  CD spectra of HSA in the presence of DAPIM.  Conditions: HSA, 0.3 g/dL; DAPIM, (a) 290 
0, (b) 2.5 µM, (c) 5 µM. 291 
 292 
Fig. 7  a) comparison of HSA results obtained by BCG method and our proposed method by 293 
Passing-Bablok regression.  b) Bland-Altman plot for the comparison of BCG method versus our 294 
proposed method.  The mean value (n=10) of the two method is plotted against the difference the 295 
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two values (our proposed method-BCG method).  The mean difference between the two methods 296 
was 0.86 g/dL.  The mean difference and the mean ± 2 SD difference were shown by solid line and 297 
dashed lines, respectively. 298 
 299 
Fig. 8  Chromatograms for a) standard solution of 0.5 g/dL HSA and b) human serum obtained by 300 






































1. Lophine-based probe (DAMIP) shows strong fluorescence when it binds with albumin. 314 
2. The binding constant of DAPIM to albumin is 3.65 x 106 M-1. 315 
3. The primary binding site of DAPIM to HSA is site II at subdomain IIIA. 316 
4. DAPIM was successfully applied to the determination of albumin in human serum. 317 
 318 
